COMMUNIQUÉS West-GlobeNewswire

Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
05/12/2017
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndrome Trial principal investigator, Dr. [...]
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
05/12/2017
PHILADELPHIA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Lindsey A. [...]
Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
05/12/2017
Data From First Dosing Cohort Show a 70% Disease Control Rate – Including 30% of Patients with Partial Responses – and Demonstrate a Tolerable Safety Profile Immunovaccine to Host a Conference Call to Review the Results [...]
Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
05/12/2017
PETALUMA, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the [...]
Photocure ASA: Presentation at the Carnegie Nordic Healthcare Day, New York
05/12/2017
Oslo, Norway, December 5, 2017 - Photocure ASA (OSE: PHO) announced today that the company will present at the Carnegie Nordic Healthcare Day, New York, on 5 December 2017. Presenter will be Ambaw Bellete, President, [...]
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
05/12/2017
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or prevent preterm birth Geneva, Switzerland and Boston, MA - December 5, 2017 - ObsEva [...]
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05/12/2017
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally active dual PI3K delta/ [...]
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017
05/12/2017
-Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: [...]
Cianna Medical Launches Comprehensive Support Program to Support Health Systems’ Mission of ‘Moving Beyond Wires’ for Breast Tumor Localization
05/12/2017
ALISO VIEJO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, today announced the launch of SCOUT Care ™ , a comprehensive training, certification and [...]
Arog Pharmaceuticals Announces Oral Presentation on Crenolanib at the 2017 American Society of Hematology Annual Meeting
05/12/2017
DALLAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet [...]
Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors
05/12/2017
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of [...]
Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting
05/12/2017
40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory Two additional self-rated secondary endpoints (CPFQ and QIDS) showed statistically significant [...]
Clementia Announces Date of Corporate Update Conference Call
05/12/2017
MONTREAL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m [...]
Clementia Annonce la Date de la Conférence Téléphonique sur sa Mise à Jour Corporative
05/12/2017
MONTRÉAL, 05 déc. 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui que la direction tiendra une conférence téléphonique et [...]
Biodesix Leaders Share Commercial and Pipeline Updates at Annual qPCR and dPCR Congress
05/12/2017
BOULDER, Colo., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Biodesix provided updates and data related to the company’s on-market and in-development liquid biopsy tests at the 2017 qPCR & Digital PCR Congress in London, UK [...]
Transactions in relation to share buyback program
05/12/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico
05/12/2017
VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. ( “CTL” ) [...]
Update on NeuroSearch’s business status and future
05/12/2017
Company announcement 5 December 2017 In the annual report for 2016, the Board of Directors informed that the Company would continue the work to dispose its remaining assets and liabilities, and that a sale of the [...]
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing
05/12/2017
THE WOODLANDS, Texas, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that it has entered into a definitive term loan agreement with BioPharma Credit PLC and BioPharma [...]

Pages